|New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease.|
|Jump to Full Text|
|PMID: 23032258 Owner: NLM Status: MEDLINE|
Related Documents :
|23177318 - Recurrent episodes of rhabdomyolysis in pontocerebellar hypoplasia type 2.
25077578 - Prolonged febrile illness and fever of unknown origin in adults.
23772568 - Leptospirosis - current risk factors connected with human activity and the environment.
23652688 - Clinical approach to known and emerging tick-borne infections other than lyme disease.
3586048 - Implications of pattern of tubal disease for microsurgery or in vitro fertilization in ...
20968148 - Polyostotic sclerosing histiocytosis (erdheim-chester disease) treated with combined ve...
|Type: Comment; Journal Article Date: 2012-10-03|
|Title: Cell cycle (Georgetown, Tex.) Volume: 11 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2012 Nov|
|Created Date: 2012-11-06 Completed Date: 2013-04-23 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States|
|Languages: eng Pagination: 3915 Citation Subset: IM|
|Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
DNA-Binding Proteins / metabolism*
Transcription Factors / metabolism*
|0/DNA-Binding Proteins; 0/Transcription Factors|
|Cell Cycle. 2012 Sep 15;11(18):3492-503
Journal ID (nlm-ta): Cell Cycle
Journal ID (iso-abbrev): Cell Cycle
Journal ID (publisher-id): CC
Publisher: Landes Bioscience
Copyright © 2012 Landes Bioscience
Print publication date: Day: 01 Month: 11 Year: 2012
pmc-release publication date: Day: 01 Month: 11 Year: 2012
Volume: 11 Issue: 21
First Page: 3915 Last Page: 3915
PubMed Id: 23032258
Publisher Id: 2012NV0798
Publisher Item Identifier: 22392
|New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease|
|Department of Medicine I and Comprehensive Cancer Center; Medical University of Vienna; Vienna, Austria
|*Correspondence to: Rotraud Wieser, Email: firstname.lastname@example.org
The oncogene Evi1, which codes for a sequence-specific transcription factor, was cloned as a target of activating retroviral insertions in murine myeloid tumors 24 y ago.1 Soon thereafter, its human homolog was found to be transcriptionally activated through rearrangements of chromosome band 3q26,2,3 which are associated with a poor prognosis in acute myeloid leukemia (AML).4 Since then, EVI1 has emerged repeatedly as retroviral integration site in different organisms, and a role of its overexpression as an indicator of poor prognosis in a variety of hematopoietic malignancies, as well as some solid tumors, has been firmly established. Because of its well-documented clinical importance, understanding the mechanism(s) of action of EVI1 is of high significance. However, EVI1 reveals its secrets only slowly, with merely 475 articles containing the search terms “EVI1,” “EVI-1” or “MECOM” (the officially assigned, but still rarely used, gene name) deposited in PubMed at the time of writing.
One of the most recent occasions on which EVI1 gained negative prominence was in the context of a human gene therapy trial for X-linked chronic granulomatous disease (X-CGD).5 Transplantation of gene-modified, autologous hematopoietic stem cells initially provided substantial clinical benefit to two young adults with X-CGD. However, over time, hematopoiesis became dominated by clones with vector integrations into, and transcriptional activation of, the EVI1 locus. These clones finally evolved into myeloid malignancies, acquiring monosomy 7, a chromosome aberration frequently associated with EVI1 overexpression in AML, during this process. As a preliminary mechanistic explanation for these findings, experimental expression of EVI1 in human diploid fibroblasts increased the numbers of cells with aberrant centrosome numbers.5
In the September 15th issue of Cell Cycle, Karakaya and colleagues confirmed and extended these observations.6 Using U2OS osteosarcoma cells inducibly expressing EVI1 as a model, they show that only 72 h after induction of EVI1, 17% of the cells contained centrosome amplifications vs. 5% of the control cells. Analysis of nuclear morphology and time-lapse video microscopy suggested that supernumerary centrosomes resulted from a cytokinesis defect that is known to activate a p53-dependent tetraploidy checkpoint. Indeed, induction of EVI1 upregulated p53 and siRNA-mediated p53 depletion increased the percentage of polyploid cells after EVI1 induction. Furthermore, the vast majority of EVI1-overexpressing cells with centrosome amplification had low or undetectable levels of the proliferation marker Ki67, indicating that EVI1-induced centrosome aberrations were largely confined to cells in G0 or early G1, and confirming that EVI1-induced tetraploidization caused a cell cycle arrest.6
These data, together with those from the X-CGD study,5 establish genomic instability as a not previously reported consequence of EVI1 overexpression, which also might explain its frequent association with monosomy 7. It should be pointed out, though, that chromosome aberrations can also emerge through selection on the background of normal missegregation rates rather than through increased genetic instability.7 In fact, in the Mitelman database,8 in ~39% of AML cases with a 3q26 aberration this was the sole cytogentic anomaly, and for ~82% of 3q26 rearranged cases, only a single clone was reported [compared with ~43% and ~83%, respectively, for the prognostically favorable t(8;21)(q22;q22)]. These data do not argue for greatly increased rates of chromosome instability as a consequence of EVI1 overexpression. However, excessive instability would likely pose the danger of lethal genetic aberrations and thus not be beneficial to a tumor cell, while low-level instability may become apparent from cytogenetic data only through more detailed analyses. In addition to eventual subtle effects on karyotype at the time of diagnosis, modest EVI1-induced chromosome instability raises the intriguing possibility that EVI1 overexpression may cause poor prognosis at least in part by facilitating acquisition of aberrations that allow tumor cells to escape chemotherapy-induced apoptosis. This hypothesis can be tested through quantitative evaluation of chromosome aberrations and clones at diagnosis and relapse (which is caused by cells that survived the initial therapy) in patients with 3q26 rearranged/EVI1 overexpressing AML and suitable controls. The work of Karakaya et al., in addition to the novel information it provides as it stands, therefore opens new perspectives that may lead to substantial advances in our understanding of how overexpression of EVI1 contributes to poor prognosis in AML and other malignancies.
Previously published online: www.landesbioscience.com/journals/cc/article/22392
|1.||Morishita K,et al. CellYear: 1988548314010.1016/S0092-8674(88)91175-02842066|
|2.||Morishita K,et al. Proc Natl Acad Sci USAYear: 19928939374110.1073/pnas.89.9.39371570317|
|3.||Fichelson S,et al. LeukemiaYear: 199269391552747|
|4.||Lugthart S,et al. J Clin OncolYear: 2010283890810.1200/JCO.2010.29.277120660833|
|5.||Stein S,et al. Nat MedYear: 20101619820410.1038/nm.208820098431|
|6.||Karakaya K,et al. Cell CycleYear: 201211349250310.4161/cc.2180122894935|
|7.||Lengauer C,et al. NatureYear: 1998396643910.1038/252929872311|
|8.||Mitelman F, et al. (2012) http://cgapncinihgov/Chromosomes/Mitelman.|
Keywords: Keywords: EVI1, MECOM, centrosome aberration, genomic instability, acute myeloid leukemia, chronic granulomatous disease, therapy resistance.
Previous Document: DNA secondary structures: stability and function of G-quadruplex structures.
Next Document: CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthol...